Research Reports | Market Assessment
March 2015

Special Report: How Are Novel Follow-On Therapies Impacting Multiple Sclerosis Treatment Paradigms in the United States?

Special Report: How Are Novel Follow-On Therapies Impacting Multiple Sclerosis Treatment Paradigms in the United States? is designed to assess and quantify the market impact of the 2014 launches of Teva’s Copaxone 40 mg three-times-weekly (3TW) and Biogen Idec’s Plegridy for the treatment of relapsing forms of multiple sclerosis (MS). Along with trial, adoption, and uptake of these disease-modifying therapies (DMTs), the report assesses U.S. neurologists’ perceptions on the uniqueness and drivers of preferential prescribing of Copaxone 40 mg 3TW and Plegridy compared with other marketed DMTs. With a potential launch of generic glatiramer acetate (GA) occurring in the next year, neurologists are also surveyed about its likely effect on MS prescribing decisions and the competitive landscape.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports